Year: 2023

Hepsor JG SIA, Hepsor AS group company, and Latvian affiliate of Bigbank AS signed a 4 million loan agreement on 08 December 2023. The purpose of the three-year loan is to finance the construction of Annenhof Majas development project in Riga. The construction and sales of the project of 40-apartments has already started and the project will be completed in the fourth quarter of 2024. „In the design of a sustainable living space valuing a green mindset, we have emphasized energy efficiency, ensuring both low utility costs and a smaller carbon footprint during the building’s operational lifespan,” said Henri Laks, a member of the Hepsor board. “A visually appealing facade solution, functional apartment layouts, an energy-efficient building with a green mindset, and a good balance of price and quality are aspects that...

PROPOSAL FOR ADOPTION OF RESOLUTIONS OF SHAREHOLDERS´ GENERAL MEETING OF AS PRFOODS WITHOUT CONVENING A MEETING          The Management board of AS PRFoods (registration code 11560713, address Pärnu mnt 141, Tallinn 11314; ISIN EE3100101031) proposes to the shareholders to adopt the shareholders’ resolutions without convening a meeting pursuant to § 2991 of the Commercial Code. Please send any questions regarding the draft resolutions to the e-mail address investor@prfoods.ee or to the address of AS PRFoods, Kärsa, Suure-Rootsi, 94129, Saaremaa, Estonia, no later than 20.12.2023. Relevant questions and answers will be published on the website of AS PRFoods www.prfoods.ee. The list of shareholders with voting rights will be fixed as at the close of business on 08.12.2023 in the Nasdaq CSD settlement system. As of the date of publication...

All amounts expressed in US dollars TORONTO, Dec. 10, 2023 (GLOBE NEWSWIRE) — Barrick Gold Corporation (NYSE:GOLD)(TSX:ABX) announced today that the Porgera mine in Papua New Guinea (PNG) is set to resume operations later this month and is expected to start pouring gold again in the first quarter of 2024. This follows the satisfaction of the conditions to the Porgera Project Commencement Agreement, in which a new ownership structure was agreed. Barrick president and chief executive Mark Bristow said the reopening of the mine represented another victory for the company’s host-country partnership model which had been very successful in Tanzania and had also been adopted for its new Reko Diq copper and gold project in Pakistan. “It’s been a long journey but in the process we have secured the buy-in of all the stakeholders and we look...

STAT3 Degrader KT-333 showed early signs of antitumor activity across liquid and solid tumors, including major responses in cutaneous T-cell lymphoma (CTCL) and Hodgkin’s lymphoma Robust STAT3 knockdown and positive immunomodulatory effect demonstrated in tumor as well as blood KT-333 was generally well-tolerated with dose escalation continuing WATERTOWN, Mass., Dec. 10, 2023 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today shared new data from its ongoing KT-333 Phase 1 trial. KT-333, a first-in-class, potent, highly selective, heterobifunctional small molecule degrader of STAT3, demonstrated early signs of antitumor activity at doses that were generally well-tolerated and associated...

ROSELAND, N.J., Dec. 10, 2023 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the pricing of an underwritten public offering of 4,765,000 shares of its common stock at a price of $0.63 per share (the “Offering”). Gross proceeds before underwriting discounts and commissions and estimated Offering expenses are expected to be approximately $3.0 million. The Offering is expected to close on December 13, 2023, subject to customary closing conditions. The Company also granted to the underwriter a 45-day option to purchase up to an additional 714,750 shares of common stock, on the same terms and conditions. Maxim Group LLC is acting as the sole book-runner for the Offering. The shares of common stock are...

Updated results presented at ASH demonstrated an 80% objective response rate and a 73% complete response (CR), with a 23-month median duration of response and 24-month median duration of CR Oral presentation showcased overall maintenance of patient-reported outcomes from baseline to 50 weeks during investigational odronextamab treatment, complementing the overall efficacy and safety profile in this heavily pretreated and highly refractory patient population TARRYTOWN, N.Y., Dec. 10, 2023 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive data for odronextamab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) from a pivotal Phase 2 trial (ELM-2). These data – which include updated efficacy, safety and patient-reported outcomes (PROs) – were presented at the 65th American...

APPLY-PNH extension data show that continuous Fabhalta® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to near-normal (≥12 g/dL), blood transfusion avoidance, and improved patient-reported fatigue in the majority of patients, with a safety profile consistent with previously reported data1–5Patients switching from anti-C5s to Fabhalta in the extension period achieved outcomes comparable to the Fabhalta arm in the 24-week randomized controlled period, including transfusion avoidance and near-normal hemoglobin-levels (≥12 g/dL) in the majority of patients1 Fabhalta was recently approved by the FDA for adults with PNH, including for both previously treated and treatment-naive patients6Basel, December 11, 2023 – Novartis today announced results from the...

Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alonePhase 3 data showed Sarclisa added to carfilzomib, lenalidomide and dexamethasone (KRd) in patients with newly diagnosed, transplant-eligible multiple myeloma resulted in 77% of patients achieving minimal residual disease (MRD) negativity after consolidation therapy, detected with a sensitivity of 10-5 MRD negativity rate measured at a sensitivity of 10-6 was 67% for Sarclisa combination therapy Results shared during oral presentation at ASH 2023 plenary scientific sessionPARIS, December 10, 2023. The Phase 3 trial investigating Sarclisa® (isatuximab) in combination with carfilzomib, lenalidomide and dexamethasone (KRd) showed a statistically significant...